OUR
PIPELINE

Kv1.3: SELECTIVE POTASSIUM
CHANNEL INHIBITOR
FOR AUTOIMMUNE
DISEASES
NEW TREATMENT FOR AUTOIMMUNE DISEASES EMPLOYING AN IMMUNE-SPARING MECHANISM OF ACTION
Autoimmune diseases place a heavy burden on society and all current medications are based on general immunosuppression. Sustained activation of effector memory T cells (TEM) plays a key role in the pathomechanism of autoimmune diseases. A unique property of these cells that they excessively rely on Kv1.3 potassium channels for persistent activation. Therefore, selective inhibition of Kv1.3 is a promising tool to treat autoimmune diseases safely and effectively without general immunosuppression.

Our lead compound has been shown to have strong in vivo effect in a rat delayed-type hypersensitivity model.
CTXA: MMP2 INHIBITOR
FOR CANCER DIAGNOSIS
AND TREATMENT
NEW ANTITUMOR MEDICATION FROM SCORPION VENOM TARGETING MATRIX METALLOPROTEINASE-2 (MMP-2)
In this project we develop new molecules for the therapy and diagnostics of MMP-2-expressing tumors, such as glioblastoma (GBM). Based on chlorotoxin (CTX), a natural miniprotein under clinical development, we developed a lead compound showing superiority in terms both affinity and selectivity compared to CTX. We filed a patent application covering a wide range of miniproteins (PCT/HU2021/050075). All claims of this application have been accepted in terms of all requirements of patentability in its International Preliminary Report on Patentability.

Our lead compound, applied as a targeting molecule in chimeric antigen receptor (CAR) T-cell therapy, has been shown to have strong effect in an in vivo glioblastoma (GBM) mouse model.

Combi-X: FIXED DOSE
COMBINATION (FDC)
PRODUCT FOR MIGRAINE
PROPHYLAXIS
DEVELOPMENT OF A FIXED-COMBINATION DRUG FOR MIGRAINE PROPHYLAXIS
Migraine, a debilitating disease affecting 17% of women and 6% of men, dramatically decreases quality of life and can cause severe temporary incapacity for work. Approximately 38% of migraine patients, having more than 2 attacks a month, would require prophylactic treatment, but current medications have serious issues. Our new fixed-dose combination utilizes drugs with good safety and tolerability profiles and expected to provide better and more cost-effective prophylactic treatment for migraineurs than currently available medications (e.g., topiramate, beta-blockers, CGRP inhibitors). Due to the different mechanism of action, it may also target cases being resistant to current therapies.

The supraadditive interaction of the constituents and thus the high in vivo efficacy of the combination have been proven in a human-relevant in vivo rat model of migraine.

CREATE:
NEW CLASS OF CNS MEDICATION EMPLOYING SMALL MOLECULE-CONTROLLED GENE THERAPY
DEVELOPMENT OF A MODIFIED RECEPTOR THAT ALLOWS PHARMACEUTICAL TARGETING OF SPECIFIC NEURONAL POPULATIONS
Chemogenetic receptors are exclusively activated by their pharmaceutical ligand (actuator). CNS-delivered chemogenetic receptors have no physiological effects without their actuator, offering a flexible and adaptive control of the timing and intensity of the effect. Providing a safe, adjustable alternative, the aim of this project is to replace some of the current neurosurgery techniques, such as deep brain stimulation and local lesion. Moreover, molecular targeting solutions (e.g. promoters) allow distinction between neuronal populations not only based on their localization, but also based on their neurochemical attributes. On the long run, non-surgical delivery may provide additional benefits to this platform. 

Our website uses cookies to provide your browsing experience and relavent informations. Before continuing to use our website, you agree & accept of our Cookie Policy & Privacy